» Articles » PMID: 22936407

Understanding the Oral Mucosal Absorption and Resulting Clinical Pharmacokinetics of Asenapine

Overview
Publisher Springer
Specialty Pharmacology
Date 2012 Sep 1
PMID 22936407
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Absorption of drugs from the oral cavity into the mucosal tissues is typically a fast event. Dissolved drugs partition into the mucosal membranes and within minutes will reach equilibrium with drug in solution in the oral cavity. However, this does not always equate to rapid drug appearance in the systemic circulation. This has been attributed to slow partitioning out of the mucosal tissues and into the systemic circulation. Based on information from literature, physicochemical properties of asenapine, and clinical data, we conclude that for sublingually administered asenapine, the exposure is primarily a function of rapid partitioning into the mucosal membranes. This is followed by slow partitioning out of the mucosal tissues and into the systemic circulation, leading to a T (max) value of about 1 h. The bioavailability of asenapine at doses below the saturation solubility in the mouth does not change and is controlled primarily by mass transport equilibrium. At doses above the saturation solubility, the bioavailability becomes more dependent not only on the distribution equilibrium but also on contact time in the mouth because additional variables (e.g. dissolution rate of the drug) need to be accounted for. These explanations are consistent with oral cavity absorption models from the literature and can be used to accurately describe the clinical data for asenapine.

Citing Articles

Evaluation of Drug Permeation Enhancement by Using In Vitro and Ex Vivo Models.

Steyn J, Haasbroek-Pheiffer A, Pheiffer W, Weyers M, van Niekerk S, Hamman J Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006008 PMC: 11859300. DOI: 10.3390/ph18020195.


In vitro and ex vivo models of the oral mucosa as platforms for the validation of novel drug delivery systems.

Macartney R, Das A, Imaniyyah A, Fricker A, Smith A, Fedele S J Tissue Eng. 2025; 16:20417314241313458.

PMID: 39944725 PMC: 11815840. DOI: 10.1177/20417314241313458.


Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma.

Yoon A, Carvajal R, Graboyes E, Kaczmar J, Albergotti W, Kejner A Front Immunol. 2025; 16:1530262.

PMID: 39931064 PMC: 11807971. DOI: 10.3389/fimmu.2025.1530262.


Therapeutic Impact of Ascorbic Acid on Oral and Periodontal Tissues: A Systematic Literature Review.

Ruzijevaite G, Acaite E, Jagelaviciene E Medicina (Kaunas). 2025; 60(12.

PMID: 39768921 PMC: 11728397. DOI: 10.3390/medicina60122041.


Eradication of proliferative verrucous leukoplakia with toll-like receptor 7 agonist (topical imiquimod): a case report.

Townsend M, Kejner A, Nourollah-Zadeh F, Rizzante F, Woods T, Rathore S Front Oncol. 2024; 14:1473889.

PMID: 39619444 PMC: 11604604. DOI: 10.3389/fonc.2024.1473889.


References
1.
Watson N, Taylor K, Joel S, Slevin M, Eden O . A pharmacokinetic study of sublingual aerosolized morphine in healthy volunteers. J Pharm Pharmacol. 1996; 48(12):1256-9. DOI: 10.1111/j.2042-7158.1996.tb03932.x. View

2.
Shahid M, WALKER G, Zorn S, Wong E . Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2008; 23(1):65-73. DOI: 10.1177/0269881107082944. View

3.
Jensen K, Mikkelsen S . Studies on the bioavailability of glyceryl trinitrate after sublingual administration of spray and tablet. Arzneimittelforschung. 1997; 47(6):716-8. View

4.
Faassen F, Vogel G, Spanings H, Vromans H . Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003; 263(1-2):113-22. DOI: 10.1016/s0378-5173(03)00372-7. View

5.
Sasaki S, Koumi S, Sato R, Murata M, Nagasawa K, Sakurai E . Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans. Gen Pharmacol. 1998; 31(4):589-91. DOI: 10.1016/s0306-3623(98)00045-7. View